Certain Warrants of NRx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 28-MAY-2024.
May 28, 2024
Share
Certain Warrants of NRx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 28-MAY-2024. These Warrants will be under lockup for 91 days starting from 27-FEB-2024 to 28-MAY-2024.
Details:
The executive officers and directors have agreed with the Representative that, subject to certain customary exceptions, without the prior written consent of the Representative, for a period commencing on the date of the lock-up agreement and ending on the date that is the 90 days after the closing of the offering, that they shall not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company.
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.